Highly dispersed Cu and Ni nano cluster sensor for ultrasensitive electrochemical detection of antiviral drug lamivudine

The accurate and rapid detection for the nucleoside reverse transcriptase inhibitor lamivudine (LAM, 3TC) in cellular systems is always a challenge in the clinic application. Here, a sensitive Cu and Ni nano cluster sensor for LAM is generated under hydrothermal conditions.The Cu and Ni atoms are highly dispersed and aggregated in the nanosized opening pore windows of the synthesized LTA zeolite, through the diatomic synergistic contribution of Cu and Ni and the enrichment of zeolitic channel pores. Using differential pulse voltammetry (DPV), the detection limit (LOD) of LAM at the potential (- 0.15 V) can reach 0.001 pM and the linear range is 0.002 pM-0.002 μM. Since the nano cluster is separated and restricted by the nanosized windows of the zeolite framework, the sensor provides high stability, good recovery (92.5-109%) and RSD (0.8-3.2%) in the analysis of tap water, RPMI 1640 medium, and rabbit serum. The Cu/Ni/LTA zeolite-modified glassy carbon electrode (Cu/Ni/LTA/GCE) exhibits excellent catalytic performance for LAM with high selectivity over potentially interfering agents. A sensitive Cu and Ni nano cluster sensor for LAM is generated in the hydrothermal condition that the Cu and Ni atoms are highly dispersed and aggregated in the nanosized opening pore windows of the as-synthesized LTA zeolite. Through the diatomic synergistic contribution of Cu and Ni and the enrichment of zeolitic channel pores, the observed limit of detection (LOD) can reach 0.001 pM under differential pulse voltammetry (DPV) method with a wide linear relationship to 0.002 μM.

Determination of antiretroviral drugs for buyers' club in Switzerland using capillary electrophoresis methods

Human immunodeficiency virus-acquired immunodeficiency syndrome continues to be a major global public health issue, having claimed almost 33 million lives to date. Due to the high cost of antiretroviral treatment, access to these drugs remains difficult for vulnerable populations, such as migrants and people living in prisons, who often do not have health insurance. These factors lead to poorer health outcomes and higher transmission rates. The personal importation scheme for unapproved generics from foreign countries is one option to access affordable human immunodeficiency virus treatment. However, the risk of importing falsified medicine remains high, and the quality control of unapproved drugs is lacking. In this context, three CE methods for the analysis of nine antiviral drugs found in commercial pharmaceutical formulations were evaluated. The selected compounds were emtricitabine, tenofovir disoproxil, tenofovir alafenamide, rilpivirine, efavirenz, raltegravir, dolutegravir, abacavir, and lamivudine. The developed methods were successfully applied to determine the active pharmaceutical ingredients of commercial formulations and unapproved generics. The quality control of unapproved generics by CE is an attractive approach due to its good standard of quality, low cost, ecofriendliness, and ease of implementation.